Form 4: VolitionRx Executive Gael Forterre Receives Stock Award in Lieu of Cash Compensation

Gael Forterre, Chief Commercial Officer of VolitionRx Ltd, received 10,240 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Summary

• On September 1, 2024, Gael Forterre, the Chief Commercial Officer of VolitionRx Ltd, was granted 10,240 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan.
• These RSUs were awarded in place of cash compensation.
• The RSUs vest in three installments of 3,414 units, 3,413 units, and 3,413 units on September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting, Forterre will receive shares of common stock equal to the number of vested RSUs.
• Following the transaction, Forterre directly owns 162,610 shares of common stock.
• Forterre also indirectly owns 5,000 shares through his spouse and 32,500 shares through Armori Capital Management, LLC, where he is the managing director and sole shareholder.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation. It's neutral in tone and doesn't indicate any significant positive or negative developments for the company.

Positives

• The award of RSUs aligns Forterre's interests with those of the shareholders, incentivizing him to contribute to the company's success.
• The vesting schedule encourages continued service and commitment from Forterre.

Industry Context

Stock awards are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the RSU award as a positive incentive for the Chief Commercial Officer.
• Employees may see this as a standard compensation practice for executives.

Key Dates